Market Analysis and Price Projections for the Drug NDC: 67871-111-01
Overview of the Drug
The drug with the NDC code 67871-111-01 is Sacrosidase, marketed under the brand name Sucraid. Sacrosidase is an enzyme derived from baker's yeast (Saccharomyces cerevisiae) and is used to treat congenital sucrase-isomaltase deficiency, a rare genetic disorder that affects the body's ability to digest certain sugars[1].
Market Context
US Pharmaceutical Market Growth
The US pharmaceutical market is projected to grow significantly, from $846.72 billion in 2022 to $1.28 trillion by 2030, with a Compound Annual Growth Rate (CAGR) of 5.36%. This growth is driven by factors such as increasing R&D investments, greater approvals of generic drugs, and the adoption of AI-based tools in drug discovery[3].
Pricing Mechanisms
National Drug Code (NDC) and Pricing
The NDC is a critical identifier for drugs, including Sacrosidase, and it plays a significant role in pricing and reimbursement. The NDC includes the labeler code, product code, and package code, which are essential for identifying the drug, its strength, and dosage form[4].
National Average Drug Acquisition Cost (NADAC)
The NADAC is a benchmark price used by Medicaid and other payers to determine reimbursement rates for drugs. For Sacrosidase, the NADAC would be calculated based on surveys of pharmacy acquisition costs, and it could be adjusted based on various factors such as changes in published pricing or inquiries to the help desk[5].
Price Projections
Current Pricing
As of the latest data, the pricing for Sacrosidase (Sucraid) would be reflected in the NADAC listings. However, specific current prices are not provided in the sources, and they would typically be found in the latest NADAC files or through direct inquiries to the manufacturer or distributors.
Future Pricing Trends
Given the overall growth in the pharmaceutical market and the specific factors influencing drug pricing, here are some trends that could impact the price of Sacrosidase:
- R&D Investments: Increasing R&D expenditures in the pharmaceutical sector could lead to higher development costs, which may be reflected in the pricing of drugs, including Sacrosidase[3].
- Generic and Biosimilar Approvals: While Sacrosidase is a biologic product, the increasing approval of generic and biosimilar drugs could put pressure on the pricing of branded biologics. However, since Sacrosidase treats a rare condition, it may be less affected by generic competition[3].
- Regulatory Changes: The FDA's proposed rule to standardize the National Drug Code (NDC) to a 12-digit format could streamline drug labeling and reduce errors, but it may also introduce short-term costs related to relabeling and system updates. These costs could potentially be passed on to consumers[2].
Market Analysis
Demand and Supply
The demand for Sacrosidase is driven by the need to treat congenital sucrase-isomaltase deficiency, a rare condition. The supply is managed by QOL Medical, LLC, the packager and distributor of Sucraid. The rarity of the condition and the specialized nature of the treatment suggest a relatively stable demand, although it is limited by the small patient population[1].
Competitive Landscape
The market for treatments of rare genetic disorders is often characterized by limited competition due to the specialized nature of the conditions. However, advancements in biotechnology and the increasing use of AI in drug discovery could lead to the development of new treatments, potentially affecting the market share of existing drugs like Sacrosidase[3].
Key Takeaways
- Market Growth: The US pharmaceutical market is expected to grow significantly, driven by R&D investments and the adoption of AI in drug discovery.
- Pricing Mechanisms: The NADAC plays a crucial role in determining reimbursement rates for drugs, including Sacrosidase.
- Future Pricing Trends: Prices may be influenced by R&D costs, regulatory changes, and the approval of generic and biosimilar drugs.
- Demand and Supply: The demand for Sacrosidase is stable but limited by the rarity of the condition it treats.
- Competitive Landscape: The market for rare genetic disorder treatments is specialized, but new technologies could introduce new competitors.
FAQs
-
What is Sacrosidase used for?
- Sacrosidase is used to treat congenital sucrase-isomaltase deficiency, a rare genetic disorder that affects the body's ability to digest certain sugars[1].
-
What is the NDC code for Sacrosidase?
- The NDC code for Sacrosidase (Sucraid) is 67871-111-01[1].
-
How is the price of Sacrosidase determined?
- The price of Sacrosidase is determined using the National Average Drug Acquisition Cost (NADAC), which is based on pharmacy acquisition costs[5].
-
What are the potential impacts of FDA's proposed NDC rule on drug pricing?
- The proposed rule to standardize NDCs to a 12-digit format could introduce short-term costs related to relabeling and system updates, which might be passed on to consumers[2].
-
How does the adoption of AI in drug discovery affect the pharmaceutical market?
- The adoption of AI in drug discovery is expected to drive growth in the pharmaceutical market by improving the efficiency and effectiveness of drug development processes[3].
Sources
-
DailyMed - SUCRAID- sacrosidase solution
-
FDA - Future Format of the National Drug Code
-
GlobeNewswire - US Pharmaceutical Market Review 2020-2023 and Forecast 2024-2030
-
FDA - National Drug Code Directory
-
Medicaid - National Average Drug Acquisition Cost (NADAC) Data Field Definitions
